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The membrane-based efflux pump systems are recognized to have an important role in pathogenicity 
and drug resistance in Mycobacterium tuberculosis by the extrusion of toxic substrates and drugs 
from the inner bacillus. This study aimed to investigate the in vitro interaction of Verapamil (VP), 
an efflux pump inhibitor, with the classical first-line anti-tuberculosis drug isoniazid (INH) in 
resistant and susceptible M. tuberculosis clinical isolates. Seven multidrug-resistant (MDR), three 
INH monoresistant and four susceptible M. tuberculosis clinical isolates were tested for the INH 
and VP combination by modified Resazurin Microtiter Assay Plate (REMA). Fractional Inhibitory 
Concentration (FIC) and Modulation Factor (MF) were determined. The INH plus VP combination 
showed no significant change in the Minimum inhibitory concentration (MIC) values of INH (FIC≥ 
0.5; MF=1 or 2).The use of VP in tuberculosis therapy should be managed carefully, considering the 
resistance caused by specific mutation in katG and inhA genes, in which the use of these EPIs may 
have no success. The use of EPIs as an adjunctive drug in the anti-tuberculosis therapy should be 
further investigated on a larger number of M. tuberculosis clinical isolates with different resistant 
profile. 
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INTRODUCTION
Drug resistance is a matter of great concern for 
tuberculosis (TB) control programs worldwide. Patients 
who harbor resistant TB must have alternative treatment 
and, in some cases, the drugs used are more expensive 
and toxic, and less effective (WHO, 2018).
The multidrug-resistant (MDR) Mycobacterium 
tuberculosis phenotype is caused by sequential mutations 
in specific chromosomal genes, which are related to the 
mechanism of rifampicin (RIF) and isoniazid (INH) 
actions (Zhang, Yew, 2009). However, the genetic basis 
of these two and other anti-TB drugs resistance are 
not fully known. In some resistant bacilli, the classical 
mutations related to resistance to specific drugs are 
not present, suggesting other resistance mechanisms 
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are responsible for the resistant phenotype (Ghajavand 
et al., 2019).
At present, the membrane-based efflux pump 
systems (EPs) are recognized to have an important 
role in the bacterial pathogenicity and antimicrobial 
resistance, including in M. tuberculosis, by the extrusion 
of toxic substrates and drugs from the inner cell. 
Nonetheless, not only have EPs important biological role 
in drug extrusion, but also in the uptake of substrates 
and nutrients necessary to the bacillus survival (Gupta 
et al., 2010a; Ghajavand et al., 2019; Rodrigues et al., 
2012; Chen et al., 2018).
These transporters can be classified as primary 
active transporters, which use ATP direct energy to 
promote the transport of molecules across the bacterial 
membrane, against their concentration gradient. The 
secondary active transporters are membrane proteins 
that use an electrochemical gradient of cations, the 
proton motive force, across the membrane coupled 
to drug extrusion against its concentration gradient 
(Sharma, Gupta, Pathania, 2019).
Verapamil (VP), a calcium channel blocker, is a 
drug commonly used to treat hypertension and has 
shown to have activity as EPs inhibitors (EPI) in M. 
tuberculosis (Machado et al., 2012). More recently, 
the M. tuberculosis’s membrane pharmacologic 
target mechanistic basis for the role of verapamil’s 
potentiation of TB drugs was recognized as having the 
ability to directly impact on membrane energetic (Chen 
et al., 2018).
In the search for new treatments in cases of 
resistant TB, in which classical anti-TB drugs are 
not effective, the combinatory use of efflux pumps 
inhibitors (EPI), such as VP, has become the subject 
of some studies (Gupta et al., 2010a; Rodrigues et al., 
2012; Cloete et al., 2018; Sharma et al., 2010). However, 
the experimental procedures for understanding EPI 
activity in M. tuberculosis are mostly limited to 
laboratory strains and few have been performed with 
clinical isolates (Machado et al., 2012), and divergence 
in results have been observed. Our study aimed to 
know how the combination of VP with the classical 
first-line anti-TB drug INH has activity, in vitro, 




A total of 14 resistant and susceptible M. 
tuberculosis clinical isolates (seven MDR, three INH 
monoresistant and four susceptible to the anti-TB first-
line drugs), previously determined by proportion method 
in Löwenstein-Jensen and genotyped by Mycobacterial 
Interspersed Repetitive Unit - Variable Number Tandem 
Repeat (MIRU-VNTR) (Supply et al., 2001) and 
Spoligotyping (Molhuizemet al.,1998), were selected 
for the study (Table I). M. tuberculosis wild type 37: 
subscribed (ATCC 27294) strain was used in all assays 
as control. Sequencing reactions, to determine mutation 
in inhA regulatory and inhA and katG structural genes, 
were conducted previously (Cardoso et al., 2004).
Minimum inhibitory concentration (MIC)
The MIC of INH and VP (Sigma-Aldrich, St. 
Louis, MO, USA) were determined, three times on 
different days for M. tuberculosis H
37
Rv and all clinical 
isolates by REMA (Resazurin Microtiter Assay Plate), 
as previously described (Palomino et al., 2002). 
Carbonyl cyanide m-chlorophenyl-hydrazone (CCCP), 
a strong protonophore, which specifically dissipates the 
transmembrane proton gradient component of the proton 
motive force, was used as EPI reference drug (Chen et al., 
2018). The drugs concentrations ranged from 0.0009 to 
50.0 μg/mL, 3.90 to 500.0 μg/mL and 0.39 to 100.0 μg/mL 
for INH, VP and CCCP, respectively. Growth and sterility 
controls for M. tuberculosis H
37
Rv and all clinical isolates 
were carried out in all assays. MIC was defined as the 
lowest drug concentration that prevented a color change of 
resazurin from blue to pink. Isolates with MIC ≥ 0.25 μg/
mL were considered INH resistant (Palomino et al., 2002).
Drugs Combination assay
The combination of VP and CCCP with INH were 
performed using VP and CCCP at constant concentration 
(½ x MIC previously determined by REMA). For the 
assay, 100 μL of OADC-supplemented Middlebrook 
7H9 (Difco Laboratories, Detroit, MI, USA) were 
added to each well in the microtiter plates and two-fold 
serial dilutions of INH were carried out. Mycobacterial 
inoculums were standardized with 1 McFarland scale 
and diluted (1:20) in OADC-supplemented Middlebrook 
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TABLE I - Mycobacterial Interspersed Repetitive Unit (MIRU) and Spoligotyping patterns, drugs susceptibility profiles, katG 
and inhA mutations in Mycobacterium tuberculosis H
37
Rv and clinical isolates





Rv - - S - -
9S - - S - -
46 224326132323 777777774020771 S - -
47 123323132321 777777777760771 S - -
25252 - 000000007760771 S - -
34R 122222153321 777777777760771 INHR Ser 315Thr NM
91R - 677737607760771 INHR Ser 315Thr NM
4250 - 777777777760710 INHR Ser315Ile NM
64A 124325163322 677737607760771 INHR/RIFR NM c to t at -15; Ile21Thr
73A 224225123321 677737607760771 INHR/RIFR/PZAR Ser315Thr NM
109 224326153325 776177607760771 INHR/RIFR Ala109Val NM
18 224326153324 776177607760771 INHR/RIFR/EMBR Ser315Thr NM
19 224327153324 776177607760771 INHR/RIFR/EMBR Ser315Thr NM




NM c to t at -15; Ile21Thr
S, susceptible; R, resistant; INH, isoniazid; RIF, rifampicin; EMB, ethambutol; PZA, Pyrazinamide; STR: streptomycin; ETH: 
ethionamide katG, gene that encode Catalase peroxidase enzyme; inhA, gene that encode the enoyl ACP reductase NADH 
dependent enzyme; -, not performed; NM, no mutation detected. 
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7H9 (BBL/Becton Dickinson, Sparks, MD, USA) added 
of VP or CCCP to achieve ½ x MIC final concentration 
in all microplates wells. The final concentration of INH 
in the microplates wells ranged from 0.0009 to 50 μg/
mL. Growth and sterility controls for M. tuberculosis 
H
37
Rv and all clinical isolates were carried out in all 
assays. Incubation conditions and reading were carried 
out according to REMA (Palomino et al., 2002).
The effect of VP and CCCP on the activity of 
INH were determined by the fractional inhibitory 
concentration (FIC) according to Pillai et al. (2005), 
where FIC=MIC drugs combination/MIC INH. The 
results were interpreted according to Coelho et al. 
(2012), considering FIC ≤ 0.25 as synergism, FIC > 0.25 
<2 as indifferent, and FIC ≥ 2 as antagonism. To quantify 
the effect of each inhibitor (VP and CCCP) in reducing 
the INH MIC values, the modulation factor (MF) was 
applied by dividing the MIC value determined for INH 
by the MIC obtained with the INH plus EPI combination 
(MF=MIC INH/MIC INH+EPI). A four-fold reduction 
on the MIC value of the INH combined with VP or 
CCCP (MF value ≥ 4) was considered significant for 
INH in having better action against the bacillus.
RESULTS AND DISCUSSION
Table II shows MIC values of INH, VP, CCCP 
and INH combined with the two EPIs at constant 
concentration for M. tuberculosis H
37
Rv and all studied 
isolates. All isolates were genetically differentiated and 
the presence of mutation in specific genes related with 
resistance to INH was known. The resistant isolates that 
had Ser315Thr or Ser315Ile mutations in the Catalase 
enzyme (katG) showed MIC range from 3.125 to 12.5 
μg/mL. The isolate with Ser 109Val mutation in katG 
had lower INH MIC, 1.56 μg/mL. These MIC values, 
obtained in our study, corroborate with the literature 
inferring resistance to INH in M. tuberculosis. The 
cumulative mutations in the regulatory region and in the 
open reading frame of inhA certainly could induce the 
MIC value observed for the two INH resistant isolates 
64A and 3614 (Walker et al., 2015).
Analyzing the MIC of VP and CCCP, in susceptible 
and in resistant isolates, lower values were detected for 
CCCP than VP. This assay was previously carried out 
for all isolates to determine the ½ x MIC concentration 
to perform the drugs combination assays.
As far as we have knowledge, both VP and CCCP 
are inhibitors of secondary active transporters. This 
kind of transporters act extruding different compounds 
by using an electrochemical gradient of cations, the 
proton motive force, across the cell membrane inducing 
extrusion against its concentration gradient. VP can 
modify the proton-motive force of the cell membrane, 
which is an essential requirement for the function of 
specifics EPs. Then, VP blocks the activity of EPs and 
the concentration of antimicrobial agents inside the 
cells will be higher and may cause bacterial death (van 
Bambeke, Balzi, Tulkens, 2000).
The effects of VP and other EPIs on reducing 
the drug resistance in M. tuberculosis, have been 
previously reported (Gupta et al., 2010b; Rodrigues 
et al., 2012; Cloete et al., 2018; Machado et al., 2012; 
Sharma et al., 2010). However, we must emphasize that 
the M. tuberculosis isolates in the above studies were 
laboratory-induced resistant mutants, which showed 
EPs (over)expression under drug pressure status, such as 
prior bacillus exposure to sub-inhibitory concentrations 
of drugs (Rodrigues et al., 2012; Sharma et al., 2010).
Like other studies (Coelho et al., 2015; Machado 
et al., 2016), the combination of VP with INH in our 
work showed no significant change in the MIC values 
of INH (FIC ≥ 0.5; MF = 1 or 2) in the studied clinical 
isolates (Table II). Coelho et al. (2015), working with 
clinical isolates, observed a MF = 4 only for the pan 
susceptible reference strain H
37
Rv, which had an initial 
MIC 0.1 μg/mL for INH and, after the addition of VP at 
¼ MIC concentration, the MIC value for INH decreased 
to 0.025 μg/mL. In our study, the used H
37
Rv reference 
strain showed a lower initial MIC 0.06 μg/mL, and no 
decrease in this value after the addition of VP at ½ MIC 
concentration was observed. Machado et al. (2016) in 
the same field of study, observed excellent action of 
VP in decreasing the MIC of INH in only one resistant 
isolate, which had a MF = 20. No interference of VP, in 
this sense, was observed in the susceptible H
37
Rv and 
in the INH resistant H
37
Rv mutant. Of course, we could 
not fail to see, in the above study, a little decrease in the 
INH MICs values in the other isolates, which account 
for a MF = 3 in three resistant isolates.
Despite the limitation of using a low number 
of clinical isolates in our study, the addition of VP 
at ½ x MIC concentration did not enhance the INH 
activity in all M. tuberculosis (FIC ≥ 0.5; MF = 1 and 
2) studied. The result of no significant reduction of the 
INH MIC by the combination with VP might be due 
to the studied isolates, which had specific mutation in 
the katG or inhA genes. Our data corroborates with 
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TABLE II - Minimum inhibitory concentration (MIC) of Isoniazid and efflux pump inhibitors alone and in combination with ½ 
x MIC of efflux pump inhibitors, Fractional Inhibitory Concentration (FIC) and Modulation Factor (MF) for Mycobacterium 
tuberculosis H
37








CCCP VP INH INH+CCCP INH+VP INH+CCCP INH+VP INH+CCCP INH+VP
H
37
Rv 3.125 125 0.06 0.03 0.03 0.5 0.5 2 2
9S 1.56 62.5 0.06 0.03 0.03 0.5 0.5 2 2
46 1.56 125 0.03 0.03 0.03 1 1 1 1
47 3.125 250 0.06 0.06 0.03 1 0.5 1 2
25252 1.56 62.5 0.125 0.06 0.125 0.48 1 2 1
34R 3.125 125 6.25 3.125 6.125 0.5 1 2 1
91R 1.56 62.5 12.5 12.5 12.5 1 1 1 1
4250 1.56 125 6.25 6.25 3.125 1 0.5 1 2
64A 1.56 125 12.5 6.25 6.25 0.5 0.5 2 2
73A 3.125 125 6.25 3.125 3.125 0.5 0.5 2 2
109 1.56 125 1.56 1.56 1.56 1 1 1 1
18 0.78 125 3.125 3.125 3.125 1 1 1 1
19 1.56 62.5 3.125 1.56 3.125 0.5 1 2 1
71A 3.125 125 12.5 6.25 6.25 0.5 0.5 2 2
3614 3.125 62.5 6.25 6.25 3.125 1 0.5 1 2
INH, isoniazid; VP, verapamil; CCCP, Carbonyl cyanide m-chlorophenyl-hydrazone. REMA: Resazurin Microtiter Assay Plate.
Machado et al. (2016), who found a limited effect of 
VP and other EPIs in isolates harboring mutation in 
inhA and little or no effect in isolates with mutation 
in katG, in which those mutations can induce low and 
high level resistance, respectively.
Although our and other in vitro studies have shown 
low effectiveness of the INH and VP combination in 
some M. tuberculosis isolates, studies in animal model, 
combining VP at a dosage of 6.25 mg/kg restored the 
susceptibility to this classical first-line anti-TB drug 
in mice infected with MDR M. tuberculosis (Louw 
et al., 2011). Additionally, an in vitro study with M. 
tuberculosis infected macrophages (Machado et al., 
2016) showed EPIs cause alterations in the transport 
of cations in eukaryotic vacuolar efflux pumps and 
enhancement of the macrophages mediated the killing 
of the bacillus. This effect in the macrophage associated 
with the proposed direct interference of the EPIs, as VP, 
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on the bacterial cell energy (Black et al., 2014, Chen et 
al., 2018) could improve the TB therapy.
In the opinion of these authors, there is no doubt on 
EPs role as an alternative mechanism for anti-TB drug 
resistance in some M. tuberculosis clinical isolates, or 
even influence to acquire other resistance mechanisms. 
However, a consideration on the lack of influence of 
VP on restoring INH susceptibility in some MDR M. 
tuberculosis isolates is clear in our study. The resistance 
in these isolates is consequence of mutations in the 
katG and inhA genes and, even VP having the ability 
to directly impact bacillus membrane energetics, no 
synergism with INH plus VP could be observed.
As no effect in decreasing the MIC of INH by the 
addition of VP, including with our EPI control, CCCP, 
was observed in our study with susceptible and resistant 
clinical isolates, it is clear that the activity of VP in 
the acquisition, as well as in the maintenance of INH 
resistance in the M. tuberculosis clinical isolates studied 
is only one of the involved mechanisms, as reported 
by Song and Wu (2016). Then, the consideration of 
efflux activity and the use of EPI in therapy of TB 
still need further studies on a larger number of MDR 
M. tuberculosis isolates with different resistant genetic 
profiles. The use of VP in the therapy of TB should be 
managed carefully, considering the resistance caused by 
specific mutations in katG and inhA genes or other genes, 
which may lead to the failure of the use of these EPIs. 
The use of EPIs as adjunctive anti-TB therapy should 
be more investigated and the issue of their activity in 
infected macrophage and in reducing anti-TB drugs side 
effects considered. 
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